Starting treatment: latest news

Starting treatment resources

Starting treatment features

Starting treatment in your own words

Starting treatment news from aidsmap

  • Restoring and maintaining a high CD4 count possible for vast majority of people living with HIV in France

    A large French study has shown that the vast majority of people living with HIV who started treatment since 2000 in a national cohort achieved a CD4 cell count in the normal range within three to four years of ...

    12 November 2014 | Alain Volny-Anne
  • What are the barriers that could stop HIV treatment becoming HIV prevention?

    One of the key strategies involved in trying to bring an end to the HIV epidemic is to increase the proportion of HIV-positive people on antiretroviral therapy (ART), to the point where suppressing their viral load starts to ...

    12 November 2014 | Gus Cairns
  • Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up

    Treatment with a triple antiretroviral combination containing once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the HIV Drug ...

    10 November 2014 | Alain Volny-Anne
  • Doravirine works as well as efavirenz with fewer CNS side-effects

    Once-daily doravirine (MK-1439), an experimental NNRTI, demonstrated viral suppression similar to that of efavirenz at 48 weeks, and the dose selected for further development was associated with fewer central nervous system (CNS) side-effects, researchers reported last week at the HIV ...

    10 November 2014 | Liz Highleyman
  • Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?

    First-line antiretroviral regimens containing emtricitabine have superior virological efficacy to combinations containing lamivudine when combined with tenofovir and either nevirapine or efavirenz, Dutch investigators report in the online edition of Clinical Infectious Diseases.The findings were also presented by Casper Rokx ...

    03 November 2014 | Michael Carter
  • NNRTIs and protease inhibitors both good for first ART, channelling affects choices

    Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and boosted protease inhibitors work equally well for people starting HIV treatment for the first time, with similar viral suppression, CD4 cell gains, and disease progression, according to a large meta-analysis presented at IDWeek 2014 earlier this month in Philadelphia, United States. ...

    22 October 2014 | Liz Highleyman
  • South African women living with HIV subtype C experience rapid CD4 cell loss

    A third of women living with HIV subtype C have a fall in their CD4 count to below 350 cells/mm3 within a year of seroconversion, investigators report in the online edition of Clinical Infectious Diseases. The World Health Organization ...

    05 August 2014 | Michael Carter
  • Efavirenz use not linked to neurocognitive impairment

    People who use antiretroviral regimens containing efavirenz (Sustiva or Stocrin, also in the Atripla coformulation) were not at higher risk for impaired neurocognitive function, either overall or when looking at specific functional domains, researchers reported on Thursday at the 20th ...

    25 July 2014 | Liz Highleyman
  • Dolutegravir demonstrates good efficacy despite resistance

    Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who had virus with resistance to NRTIs. Among people starting treatment for the first time, no resistance was ...

    24 July 2014 | Liz Highleyman
  • Could HIV treatment mean safer sex?

    A meta-analysis of every study that has looked at the sexual behaviour of people after starting HIV treatment has found not a single instance of so-called ‘risk compensation’ – the idea that if people start taking HIV treatment ...

    24 July 2014 | Gus Cairns
More news

Starting treatment news selected from other sources

  • How San Francisco Is Getting to Zero On HIV

    San Francisco is already making progress when it comes to HIV prevention, treatment and retention. In 2006, San Francisco had 517 new HIV cases; by 2013, that number dropped to 359, a 30 percent decrease. The number of deaths almost halved between 2006 and 2013, going from 327 to 182. Additionally, compared to the United States, San Francisco is faring better in multiple aspects of the HIV care continuum: in 2012, 82 percent of HIV positive individuals in the U.S. were aware of their status; in San Francisco, that number was 94 percent.

    11 December 2014 | Huffington Post
  • Starting HIV Meds Within a Year of Infection Helps Restore CD4s

    Beginning treatment for HIV within a year of infection improves the likelihood of returning an individual’s CD4 count to a normal level.

    03 December 2014 | AIDSMeds
  • CDC Analyzes Impediments to Viral Suppression in People With HIV

    The CDC has reframed the HIV treatment cascade figures to highlight the various reasons why only 30 percent of Americans have a fully suppressed virus.

    03 December 2014 | POZ
  • Does ‘treat’ always follow ‘test’? Why some people do not want HIV treatment

    In South Africa, only one third of individuals living with HIV are actually on treatment. Treatment refusal has been identified as a phenomenon among people who are asymptomatic, however, factors driving refusal remain poorly understood.

    01 December 2014 | UNAIDS Science Now
  • IRIS uncommon when ART starts in 96,000-person EuropeUS study

    Immune reconstitution inflammatory syndrome (IRIS) appears to be rare when antiretroviral-naive adults in Europe and the United States start ART, with the possible exception of mycobacterial infections.

    01 December 2014 | International AIDS Society
  • Only three in 10 Americans have HIV under control: government report

    Just 30 percent of Americans living with HIV have the virus in check, putting others at risk of infection, U.S. health officials said yesterday. The report by the U.S. Centers for Disease Control and Prevention (CDC) found that 840,000 of the 1.2 million people infected with HIV in 2011 were not consistently taking anti-HIV drugs that keep the virus suppressed at very low levels.

    26 November 2014 | Reuters
  • START Study Could Change How We Look at HIV Treatment, and HIV Itself

    Have you heard of the START (Strategic Timing of Antiretroviral Treatment) study? In my opinion, it is probably the most important study currently running. It generates strong views, both for and against initiating antiretroviral therapy early, but the results are likely to be surprising.

    25 November 2014 | The Body
  • NNRTI + 3 NRTIs may be strong first regimen in UK/Ireland children

    Children starting antiretroviral therapy (ART) with a nonnucleoside (NNRTI) plus 3 nucleosides (NRTIs) had the lowest 2-year virologic failure rate in a study of 997 children in the United Kingdom and Ireland. Five-year toxicity rates were similar with the NNRTI and protease inhibitor (PI) regimens studied.

    24 November 2014 | International AIDS Society
  • Early Initiation of Combo Antiretrovirals Gaining Support

    Evidence continues to support the initiation of combined antiretroviral therapy soon after HIV infection, researchers report. In fact, the likelihood of the CD4/CD8 ratio normalizing was almost three times greater if antiretroviral therapy was initiated within 6 months of HIV infection than if it was delayed for more than 6 months, according to John Thornhill, MD, from Imperial College London in the United Kingdom, and his team.

    07 November 2014 | Medscape (requires registration)
  • Effective treatments available for HIV patients not eligible for efavirenz regimens

    HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy, a new American clinical trial found. The finding is important for patients who are not eligible for treatment with efavirenz, including women considering becoming pregnant and patients with a history of severe psychiatric disorders.

    07 October 2014 | Science Daily
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.